Association between IGVH gene status and other prognostic factors
| Factor . | Mutated N = 123 . | Unmutated N = 82 . | Odds ratio (95% CI) . | P . |
|---|---|---|---|---|
| Sex-male | 49% (60) | 71% (58) | 2.5 (1.4, 4.6) | .003 |
| Abnormal karyotype | 60% (74) | 83% (67) | 3.2 (1.6, 6.3) | .001 |
| Karyotype evolution present | 18% (19) | 29% (18) | 1.9 (0.9, 3.9) | .15 |
| Atypical morphology | 18% (21) | 59% (47) | 6.6 (3.5, 12.7) | < .001 |
| CD38 ≥ 30% | 25% (27) | 72% (44) | 8.0 (3.9, 16.2) | < .001 |
| Disease stage | < .001 | |||
| A | 93% (114) | 67% (55) | 1.0 | |
| B | 2% (3) | 22% (18) | 12.4 (3.5, 44.0) | |
| C | 5% (6) | 11% (9) | 3.1 (1.1, 9.2) | |
| Chromosome 13 abnormal | 53% (64) | 29% (24) | 0.4 (0.2, 0.7) | .002 |
| Chromosome 12 abnormal | 22% (26) | 45% (35) | 2.9 (1.6, 5.5) | .001 |
| Chromosome 11 abnormal | 8% (9) | 20% (16) | 3.1 (1.3, 7.4) | .02 |
| Chromosome 17 abnormal | 5% (6) | 14% (9) | 2.8 (1.0, 8.4) | .09 |
| Factor . | Mutated N = 123 . | Unmutated N = 82 . | Odds ratio (95% CI) . | P . |
|---|---|---|---|---|
| Sex-male | 49% (60) | 71% (58) | 2.5 (1.4, 4.6) | .003 |
| Abnormal karyotype | 60% (74) | 83% (67) | 3.2 (1.6, 6.3) | .001 |
| Karyotype evolution present | 18% (19) | 29% (18) | 1.9 (0.9, 3.9) | .15 |
| Atypical morphology | 18% (21) | 59% (47) | 6.6 (3.5, 12.7) | < .001 |
| CD38 ≥ 30% | 25% (27) | 72% (44) | 8.0 (3.9, 16.2) | < .001 |
| Disease stage | < .001 | |||
| A | 93% (114) | 67% (55) | 1.0 | |
| B | 2% (3) | 22% (18) | 12.4 (3.5, 44.0) | |
| C | 5% (6) | 11% (9) | 3.1 (1.1, 9.2) | |
| Chromosome 13 abnormal | 53% (64) | 29% (24) | 0.4 (0.2, 0.7) | .002 |
| Chromosome 12 abnormal | 22% (26) | 45% (35) | 2.9 (1.6, 5.5) | .001 |
| Chromosome 11 abnormal | 8% (9) | 20% (16) | 3.1 (1.3, 7.4) | .02 |
| Chromosome 17 abnormal | 5% (6) | 14% (9) | 2.8 (1.0, 8.4) | .09 |